ClinicalTrials.gg
RecruitingNCT05540834VETtiPAT-ARFUpdated Apr 17, 2024

Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure

A Phase 2 interventional study of Alteplase in Acute Respiratory Failure, Hypercoagulability and Fibrinolysis Shutdown, sponsored by South West Sydney Local Health District. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by South West Sydney Local Health District · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled May 2022, registered Aug 2022).
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.

Read the detailed description

Acute respiratory failure (ARF) due to COVID is associated with an increased risk of thrombosis causing death. Therapeutic heparin administration was not beneficial in the critically ill.

In non-COVID ARF patients, the presence of multiple pulmonary vessel filling defects associated with the severity of disease and patient outcome, and resolved following the administration of the fibrinolytics, streptokinase and urokinase. An early phase I study reported improved oxygenation in patients with severe ARF following administration of plasminogen activators. The rationale for fibrinolytics in ARF has been published previously and is supported by meta-analysis of preclinical studies.

In both non-COVID and COVID associated ARF, defective fibrinolysis has been demonstrated. Standard coagulation tests cannot identify a hypercoagulable state nor assess fibrinolysis whereas viscoelastic testing (VET), a rapid, point-of-care device commonly used in Intensive Care, is able to detect these disorders. Numerous studies have demonstrated that VET is sufficiently sensitive to detect the coagulopathies associated with ARF, with several parameters associating with disease severity.

The VETtiPAT ARF trial uses VET to identify ARF patients with a procoagulant and hypofibrinolytic phenotype, then to guide tPA (Alteplase) administration thus maximising efficacy and safety through a personalised precision medicine approach.

02

Conditions studied

  • Acute Respiratory Failure
  • Hypercoagulability
  • Fibrinolysis Shutdown

Browse trials for

03

In context

Thrombophilia

88 studies on the registry are indexed under Thrombophilia; 13 are open to participants now.

This study's planned enrollment of 70 is below the median of 86 across 29 interventional studies indexed under Thrombophilia.

Browse Thrombophilia studies →

Lead sponsor

South West Sydney Local Health District is the lead sponsor of 16 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute respiratory failure of primary pulmonary infectious or extrapulmonary infectious aetiology with severity graded by the arterial oxygen partial pressure to inspired fraction of oxygen ratio (P/F) as per the Berlin definition: acute onset of hypoxemia with an arterial partial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2) ratio of less than or equal to 300 mmHg with positive end expiratory pressure (PEEP) of 5 cm of water (H2O) or greater
  2. Requiring admission to Intensive Care
  3. Aged 18 - 75 years of age
  4. Procoagulant profile on ClotPro (TradeMark) fibrinogen (FIB)-test +/- extrinsic coagulation pathway (EX)-test - above normal range for amplitude at 10 minutes (A10) and/or maximal clot firmness (MCF) at 30 minutes run time
  5. Lysis Time on ClotPro tissue plasminogen activator (TPA)-test ClotPro equal to or greater than 365 seconds

Exclusion criteria

Exclusion Criteria:

  1. count \<150 x 109/L or a reduction in platelet count of 50% or more in the last 24 hours
  2. Body weight \< 60 kg
  3. Structural intracranial disease e.g. arterio-venous malformation or aneurysm
  4. Previous intracranial haemorrhage
  5. Ischaemic stroke within 3 months
  6. Traumatic cardiopulmonary resuscitation
  7. Hypoxaemia from traumatic lung injury
  8. Active or recent bleeding
  9. Recent surgery, trauma or invasive procedure
  10. Systolic blood pressure (BP) > 180 mm Hg
  11. Diastolic BP > 100 mm Hg
  12. Pericarditis or pericardial fluid
  13. Diabetic retinopathy
  14. Currently menstruating
  15. Pregnancy - (beta-human chorionic gonadotropin (HCG) to be performed if of child-bearing age)
  16. Liver failure (known severe liver disease or an or an aspartate aminotransferase level that is 5 times the )
  17. Kidney failure (estimated (eGFR =\<30 mL/hr or receiving renal replacement therapy)
  18. Use of therapeutic anticoagulation or platelet antagonists
  19. Not for active treatment
  20. Unlikely to survive until the day after tomorrow
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    VET guided tPA administration + standard care

    Actilyse (tPA) will be administered as a 2-hour bolus then low dose infusion over 24 hours (safety and dose-finding stage) and 72 hours (randomised stage). Regular monitoring of the coagulation status and lysis time using VET will enable increases or decreases/cessation of the dose. Prophylactic low molecular weight heparin will continue throughout.

    Drug: Alteplase

  • No intervention
    Standard care

    Patients will receive standard care for their condition including prophylactic low molecular weight heparin. Coagulation status and lysis time monitoring with VET will occur at the same times as the experimental arm.

Interventions

06

What researchers measure

Primary outcomes

  1. Change in clot lysis time on viscoelastic testing from baseline and up to 72 hours

    The impact of alteplase administration on the clot lysis time (in seconds) measured by the TPA-test using the ClotPro at the bedside

    Time frame: From start to end of alteplase infusion + 1 and up to 72 hours later/ equivalent timeframe in controls

Secondary outcomes

  1. Change in VET coagulation parameters from baseline and up to 72 hours

    The impact of alteplase administration on clot formation related to fibrinogen and the extrinsic pathway (maximum clot firmness (MCF) / amplitude at 10 minutes (A10) in millimeters) measured by the FIB-test and EX-test using the ClotPro at the bedside

    Time frame: From start to end of alteplase infusion + 1 and up to 72 hours later/ equivalent timeframe in controls

  2. Changes in oxygenation

    Arterial partial pressure of oxygen to inspired fraction of oxygen (P/F) ratio

    Time frame: From start to end of alteplase infusion/ equivalent timeframe in controls

  3. Rate of participants with bleeding events

    Any bleeding events Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater

    Time frame: From study entry to Day 5

  4. Rate of thromboembolic events

    Any thromboembolic event

    Time frame: From study entry to Day 30 or hospital discharge, whichever occurs first

  5. Changes in organ function

    Sequential Organ Failure Assessment (SOFA) score from 0 (normal) to a range of 1-4 with higher scores indicating more severe organ dysfunction

    Time frame: From start to end of alteplase infusion/ equivalent timeframe in controls

07

Study locations

1 of 1 sites recruiting
  • Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District
    Liverpool, New South Wales 1871, Australia
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for May 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Sep 15, 2022
StartActual
May 18, 2022
Primary completionEst.
May 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05540834
Lead sponsor
South West Sydney Local Health District
Responsible party
Anders Aneman (Professor, South West Sydney Local Health District) — Principal investigator
First posted
Sep 15, 2022
Start date
May 18, 2022
Primary completion
May 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 17, 2024

Study contacts

Anders Aneman
Contact
Anders.Aneman@health.nsw.gov.au
+61 427915693
Lucy Coupland
Contact
l.coupland@unsw.edu.au
+61 419723330
Anders Aneman
principal investigator · Sydney WAHS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tissue Plasminogen Activator

Start the discussion